MIRA Pharmaceuticals, Inc. Common Stock Asset Resilience Ratio
MIRA Pharmaceuticals, Inc. Common Stock asset resilience ratio. MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has an Asset Resilience Ratio of 54.91% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MIRA Pharmaceuticals, Inc. Common Stock defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of MIRA Pharmaceuticals, Inc. Common Stock (2024–2025)
Asset resilience ratio of MIRA Pharmaceuticals, Inc. Common Stock from 2024 to 2025. This chart shows how MIRA Pharmaceuticals, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read total liabilities of MIRA Pharmaceuticals, Inc. Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down MIRA Pharmaceuticals, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of MIRA Pharmaceuticals, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.50 Million | 54.91% |
| Total Liquid Assets | $4.50 Million | 54.91% |
Asset Resilience Insights
- Very High Liquidity: MIRA Pharmaceuticals, Inc. Common Stock maintains exceptional liquid asset reserves at 54.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MIRA Pharmaceuticals, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MIRA Pharmaceuticals, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
MIRA Pharmaceuticals, Inc. Common Stock Asset Resilience Ratio by Year (2024–2025)
MIRA Pharmaceuticals, Inc. Common Stock asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for MIRA Pharmaceuticals, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.21% | $4.68 Million | $11.09 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $2.92 Million | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical mar… Read more